Arcadia Biosciences, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
RKDA$0.16-3.5%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $4,178 | $259 |
| Short-term investments | — | 4,304 |
| Accounts receivable and other receivables, net of allowance for credit loss of $559 as of June 30, 2026 and December 31, 2025 | 559 | 425 |
| Inventories | 930 | 1,212 |
| Prepaid expenses and other current assets | 72 | 156 |
| Total current assets | 5,739 | 6,356 |
| Property and equipment, net | — | 8 |
| Intangible assets, net | 39 | 39 |
| Other noncurrent assets | 115 | 143 |
| Total assets | $5,893 | $6,546 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,383 | $1,789 |
| Other current liabilities | 263 | 270 |
| Total current liabilities | 1,646 | 2,059 |
| Common stock warrant and option liabilities | 3,614 | 347 |
| Total liabilities | 5,260 | 2,406 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value—150,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 2,181,715 and 1,373,120 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 66 | 65 |
| Additional paid-in capital | 292,435 | 285,292 |
| Accumulated deficit | (291,868) | (281,217) |
| Total stockholders' equity | 633 | 4,140 |
| Total liabilities and stockholders’ equity | $5,893 | $6,546 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.